MAPI Research Trust provides reliable, comprehensive and up-to-date information services to research scientists, pharmaceutical companies, and governmental health agencies involved in the fields of Patient-Reported Outcomes (PRO) and Epidemiology worldwide.
Home SERVICES Questionnaire Licensing
HIV-SQUAD (Symptom Quality of Life Adherence) Questionnaire®


Developed by:
Abbott France

Objective:
Simplified HIV patient questionnaire

Copyright:
HIV-SQUAD® ABBOTT FRANCE, Octobre 2008. All rights reserved.

Reference publication:
B. Spire, B. Arnould, F. Barbier, J. Durant, et al. Simplification and first validation of a short battery of patient questionnaire for clinical management of HIV-infected patients: the HIV-SQUAD® (Symptom Quality of life Adherence) Questionnaire®. HIV Clin Trials. 2009 Jul-Aug;10(4):215-32.

Acknowledgement:
The HIV-SQUAD® (Symptom Quality of life Adherence) Questionnaire® is a battery of questionnaires derived from the WHOQOL-HIV BREF, the symptoms due to HAART questionnaire and the APROCO Adherence Questionnaire for which information on - or permission to use - shall be sought to their respective developers.


Conditions of use:

1. User Agreement

User is required to complete and sign a User Agreement in which specific conditions requested by the Authors are detailed.

2. Access fees

carre6 Authors' royalty fees are requested according to the study design and context of use of the questionnaire:

- In academic research and individual clinical practice: free of charge

- In commercial studies (1) involving "for-profit" organizations: 1,000 €* per protocol/application + 500 €* per existing language version

Other specific conditions requested by the Authors are detailed in the User Agreement.


carre6 Distribution fees are requested according to the study design and context of use of the questionnaire:

- In not-funded academic research (1) and individual clinical practice: free of charge

- In funded academic research (2): 300 €* per study + 50 €* per language version requested

- In commercial studies (1) involving "for-profit" organizations and academic studies funded by commercial companies: 600 €* per study + 250 €* per language version requested.


* excluding VAT

(1) Not funded academic research: if the project is not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds then fees are waived.

(2) Funded academic research: projects receiving funding from commerce, government, EU should anticipate paying the corresponding fees.

(3) Commercial studies (industry, CRO, any for-profit companies)


Review copy:

Original French version available for review purpose only. Please click here to access.


New translations:

For the production of new translations to be used in commercial studies, each translation shall be coordinated by MAPI Institute.


Contact information:

MAPI Research Trust

27 rue de la Villette
F - 69003 LYON
Tel: +33 4 72 13 65 75
Fax: +33 4 72 13 55 73

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Please have the User Agreement completed, dated and signed and return one original copy to MAPI Research Trust by post. As soon as we receive it, we will process your request.

More information on the HIV-SQUAD® on PROQOLID


[ BACK ]

 

To access our catalog, please click here.

New questionnaires distributed by MAPI Research Trust

ACCEPT (Chronic Treatment Acceptance Questionnaire)
MAPI SAS / Registrat MAPI (France)

ADRQL (Alzheimer Disease Related Quality of Life)
Black Betty S, Kasper Judith D and Rabins Peter V. - Johns Hopkins Medical INstitutions (USA)

Barthel Index questionnaire
The Maryland State Medical Society - MedChi (USA)

ESS (Epworth Sleepiness Scale) 
Murray W. Johns (Australia)

FIRST (Fibromyalgia Rapid Screening Tool)
Serge Perrot & Didier Bouhassira (France)

PDSS-2 (Parkinson's Disease Sleep Scale)
Ray Chaudhuri (UK) & Claudia Trenkwalder (Germany)

Skindex questionnaire 
Mary-Margaret Chren (USA)

TRIM-D and TRIM-D Device (Treatment Related Impact Measure for Diabetes)
Novo Nordisk (Denmark)